T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

NCT02062359 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped Study was closed due to poor accrual.

Conditions

Metastatic Cancer
Metastatic Melanoma

Interventions

BIOLOGICAL: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
DRUG: Aldesleukin
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]